Αποτελέσματα Αναζήτησης
Authorization (EUA) to expand use of Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) for prevention of COVID-19 caused by SARS-CoV-2 in individuals 5 through 11 years of age (hereafter 5-11...
FDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age. The FDA amended the emergency use authorizations (EUAs) of the updated (bivalent) Moderna and...
5 Σεπ 2024 · On June 17, 2022, the Food and Drug Administration (FDA) authorized an Emergency Use Authorization (EUA) for a 2-dose Moderna COVID-19 vaccine primary series for administration to children ages 6 months through 5 years. The FDA also authorized a 3rd primary series dose of the Moderna COVID-19 vaccine to children ages 6 months through 5 years ...
15 Φεβ 2023 · The observed overall vaccine efficacy against symptomatic Covid-19 in children 6 months to 4 years of age was 73.2% (95% confidence interval, 43.8 to 87.6) from 7 days after dose 3 (on...
30 Δεκ 2021 · On October 29, 2021, the Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 (BNT162b2) mRNA vaccine to expand its use to children aged 5–11 years, administered as 2 doses (10 μg, 0.2mL each) 3 weeks apart (1).
12 Νοε 2021 · On October 29, 2021, FDA issued an EUA amendment for a new formulation of Pfizer-BioNTech COVID-19 vaccine for use in children aged 5-11 years, administered as 2 doses (10 μg, 0.2 mL each), 3 weeks apart (Table) (1).
Our near–real-time monitoring results for 20 prespecified health outcomes in the pediatric population provide reassuring real-world evidence of the safety of the BNT162b2 COVID-19 vaccine in children and adolescents.
